Maven Securities LTD Acquires 25,000 Shares of Alumis Inc. (NASDAQ:ALMS)

Maven Securities LTD raised its holdings in shares of Alumis Inc. (NASDAQ:ALMS) by 100.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Maven Securities LTD’s holdings in Alumis were worth $534,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. MetLife Investment Management LLC bought a new stake in Alumis during the 3rd quarter valued at $89,000. BNP Paribas Financial Markets bought a new stake in shares of Alumis in the 3rd quarter worth $27,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Alumis in the 3rd quarter worth $1,160,000. Towerview LLC grew its stake in shares of Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after acquiring an additional 70,000 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Alumis in the 2nd quarter worth $3,376,000.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. HC Wainwright reduced their target price on shares of Alumis from $30.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Robert W. Baird started coverage on shares of Alumis in a research note on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $26.83.

Alumis Trading Down 6.7 %

NASDAQ ALMS opened at $7.99 on Thursday. Alumis Inc. has a 52 week low of $7.96 and a 52 week high of $13.53. The firm’s 50-day simple moving average is $10.67.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.